A glycation resistant insulin polypeptide and a method of preparing the same thereof
Patent Information
- Application Number
- PCT/IN2024/050292
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-03-22
- Filing Date
- 2024-03-21
- Publication Date
- 2024-11-14
Smart Images

Figure 000001 
Figure 000002 
Figure 000003
Abstract
Description
[0001] A GLYCATION RESISTANT INSULIN POLYPEPTIDE AND A METHOD OF PREPARING THE SAME THEREOF
[0002] FIELD OF THE INVENTION
[0003] The present invention broadly relates to the field of genetic engineering and biotechnology. More precisely, the present invention relates to a glycation resistant insulin polypeptide to provide an insulin analogue, polynucleotide encoding the mutated glycation-resistant insulin, method of expressing and producing the mutated glycation-resistant insulin; and use thereof, for example to reduce blood glucose and / or to treat a metabolic disease.
[0004] BACKGROUND OF THE INVENTION
[0005] Diabetes is a metabolic disorder currently affecting over 8% of the world's population, and it leads to a number of complications such as nephropathy, retinopathy, neuropathy and cardiovascular diseases which greatly affect the life expectancy and quality of life of diabetic patients. It mainly involves either insufficient secretion of insulin (Type I diabetes) or inefficient response to secreted insulin termed as insulin resistance (Type II diabetes).
[0006] Insulin therapy is the treatment of choice for Type I diabetes and has also been shown to be useful in managing some cases of Type II diabetes {Geremia et al., Endocrine Practice, 12, (Supplement 1), 105- 109, 2006} {Swinnen et al., Diabetes Care, 32, (suppl 2), S253-S259, 2009}. A number of different variants of insulin are currently in use, with plasma half-life ranging from a few minutes to over a day. Since insulin has a short half-life, it requires to be taken quite frequently in severe diabetic patients. Thus long-acting insulin such as Lente, Ultralente, and Glargine type of insulin are preferred over short acting insulin. Long-acting insulin forms are more prone to undergo glycation in the circulation due to hyperglycemic condition. Glycation of insulin reduces its activity therefore insulin that does not undergo glycation may be desirable and used especially in the development of long-acting insulin.
[0007] The main characteristic of diabetes is elevated blood glucose, which is reported to lead to high plasma protein glycation {Thomalley et al., Biochemical Journal, 344, (1), 109-116, 1999}. Glycation involves the reaction of reducing sugars like glucose with free amino groups of proteins and has been reported to affect the activity of a number of proteins {Hedrick et al., Diabetologia, 43, (3), 312-320, 2000} {Norbert et al., Current Enzyme Inhibition, 1, (1), 21-27, 2005}. Many enzymes such as Superoxide dismutase, glutathione reductase, proteases etc. have been found to have reduced activity upon glycation. Insulin itself has also been reported to undergo glycation, which leads to reduction in its biological activity {Abdel-Wahab et al., Acta Diabetologica, 34, (4), 265-270, 1997}, {Hunter et al., Diabetes, 52, (2), 492- 498, 2003} and {Lindsay et al., Diabetologia, 46, (4), 475-478, 2003}. Therefore, glycation of insulin may significantly reduce the efficiency of insulin therapy in diabetes.
[0008] Studies have reported that there are some recombinant insulin proteins which comprises mutations by adding two arginine or lysine residues, which possess higher chances of formation of glycation productions due to presence of two arginine residues or lysine. Those mutations are for improving stability of insulin and not for therapeutic activity by providing glycation resistant nature.
[0009] Long-acting insulin forms are more prone to undergo glycation in the circulation due to hyperglycemic condition. Glycation of insulin reduces its activity therefore insulin that does not undergo glycation may be desirable and should be used especially in the development of glycation resistant (may be with long acting) insulin
[0010] Therefore, there is an imminent need to design a recombinant form of insulin that does not undergo glycation may be a better alternative for insulin therapy, ultimately useful in the treatment of diabetes type I and severe diabetes type II. Since glycation mainly occurs at the free amino groups of lysine and arginine, therefore, mutation of these residues to different amino acids will prevent the glycation.
[0011] The present invention satisfies the existing needs, as well as others, and generally overcomes the deficiencies found in the prior art.
[0012] OBJECTIVES OF THE INVENTION
[0013] An objective of the present invention is to provide a recombinant insulin resistant to glycation by site directed mutagenesis of lysine and arginine residues, which is useful for developing long-acting insulin, and proinsulin thereof that have improved stability and activity.
[0014] Another objective of the present invention is to provide a mutated insulin, and proinsulin thereof that are resistant to glycation.
[0015] Another objective of the present invention is to provide a nucleic acid encoding mutated insulin, and proinsulin thereof that are resistant to glycation.
[0016] Yet another objective of the present invention is to provide an expression system producing mutated insulin, and proinsulin thereof that are resistant to glycation
[0017] Yet another objective of the present invention is to provide a recombinant method of producing mutated insulin, and proinsulin thereof that are resistant to glycation.
[0018] Yet another objective of the present invention is to provide a pharmaceutical composition comprising a mutated insulin, and proinsulin thereof that are resistant to glycation.
[0019] Yet another object of the present invention is to provide a method of treating one or more metabolic diseases including diabetes.
[0020] SUMMARY OF THE INVENTION
[0021] The present invention relates to insulin analogues. Specifically, the present invention relates to mutated insulin resistant to glycation, nucleic acids encoding mutated glycation-resistant insulin thereof, method of expressing and producing mutated glycation-resistant insulin thereof; and methods of their use, for example to reduce blood glucose and / or to treat a metabolic disease.
[0022] In one aspect, the present invention relates to a recombinant insulin resistant to glycation by site directed mutagenesis of lysine and arginine residues, for developing mutated glycation resistant insulin, and proinsulin thereof that have improved stability and activity.
[0023] In one aspect, the present invention relates to a mutated glycation-resistant insulin, and proinsulin thereof that have improved stability and activity.
[0024] In an aspect, the present invention relates to a mutated glycation-resistant insulin expressed and purified to obtain the mutant insulin having better stability and glucose-reducing ability for a longer period of time than the native insulin.
[0025] In an aspect, the present invention relates to a mutated insulin, and proinsulin thereof that are resistant to glycation.
[0026] In one aspect, the present invention relates to a mutated glycation -resistant insulin, and proinsulin thereof that may be long-acting.
[0027] In a preferred aspect, the present invention relates to a glycation resistant insulin polypeptide, and proinsulin thereof, wherein the mutations are generated by site directed mutagenesis of chain B of insulin peptide by replacing arginine or lysine or both amino acids selectively and, at the same time, maintain equivalent or better efficacy of insulin in terms of glucose control. In an embodiment, mutations are introduced at sites R22 (ARG22), K29 (LYS29), or combinations thereof. In an embodiment, the present invention discloses a glycation resistant insulin polypeptide having mutations at site R22 (ARG22) selected from the group comprising of R22A, R22C, R22D, R22E, R22F, R22G, R22H, R22I, R22L, R22M, R22N, R22P, R22Q, R22S, R22T, R22V, R22W, R22Y, R22X, and site K29 (LYS29) selected from the group comprising of K29A, K29C, K29D, K29E, K29F, K29G, K29H, K29I, K29L, K29M, K29N, K29P, K29Q, K29S, K29T, K29V, K29W, K29Y, and K29X, wherein X is designated as deletion of amino acid sequence.
[0028] The polypeptide is having sequences selected from SEQ ID NO: 1 to SEQ ID NO: 9
[0029] The mutations at site R22 are selected from the group consisting of R22A, R22S, R22N, and R22Q.
[0030] The mutations at site K29 are selected from the group consisting of K29E, K29W, K29Q and K29Y.
[0031] The polypeptide is resistant to glycation by 50% to 100%.
[0032] The polypeptide comprises 1 to 10 amino acid substitutions.
[0033] The polypeptide is having a mutation at R22, K29, or combinations thereof share at least 80% of sequence identity to SEQ NO: 1 to SEQ NO: 9.
[0034] The polypeptide is having a mutation at R22, K29, or combinations thereof share 80% to 99% sequence identity to SEQ NO: 1 to SEQ ID: 9.
[0035] In another embodiment, the present invention discloses a polynucleotide coding one or more mutated mutant insulin polypeptides as disclosed above.
[0036] In another embodiment, the present invention discloses a method for producing glycation-resistant insulin, comprising the steps of: i. identifying and cloning target gene of an insulin; ii. modifying amino acid residues R22 and K29 of B -chain of insulin obtaining a modified glycation resistant insulin polypeptide as disclosed above; iii. expressing the modified glycation resistant insulin polypeptide in a suitable expression system; and iv. purifying the expressed modified insulin precursor peptide sequence to obtain glycation -resistant modified insulin.
[0037] The mutation of step ii) in said polypeptide is generated by site directed mutagenesis of chain B of insulin peptide by substituting arginine at R22 or lysine at K29 or both amino acids selectively.
[0038] In one aspect, the present invention relates to a nucleic acid encoding mutated insulin, and proinsulin thereof that are resistant to glycation.
[0039] In another aspect, the present invention relates to an expression system producing mutated insulin, and proinsulin thereof that are resistant to glycation
[0040] In one embodiment, the present invention provides a polynucleotide coding one or more mutated mutant insulin peptides as disclosed in Table 1.
[0041] In one embodiment, the present invention provides a glycation-resistant insulin analog, wherein specific amino acid substitutions are introduced at positions critical for glycation.
[0042] In another aspect, the present invention relates to a vector that may also include one or more mutated mutant insulin peptide coding sequences and / or selectable marker genes and other genetic elements known in the art. In an embodiment, the vector can transduce, transform, or infect a cell, thereby causing the cell to express nucleic acids and / or proteins other than those native to the cell. In another aspect, the present invention relates to a recombinant method of producing mutated insulin, and proinsulin thereof that are resistant to glycation.
[0043] In another aspect, the present invention relates to a pharmaceutical composition comprising a mutated insulin, and proinsulin thereof that are resistant to glycation.
[0044] In yet another aspect, the present invention relates to a method of treating one or more metabolic diseases including diabetes.
[0045] BRIEF DESCRIPTION OF THE DRAWINGS:
[0046] FIG 1 represents the pET-28 a vector plasmid map, in accordance with an embodiment of the present disclosure.
[0047] FIG 2 represents the heat map of insilico based FoldX stability analysis of the mutations in insulin. The free energy (DDG / AAG) is a metric for predicting how a single point mutation will affect protein stability, in accordance with an embodiment of the present disclosure. Negative DDG suggests that the mutation would lead to a more stable protein. The DDG <0 kJ / mol were considered most stable among the mutants. The heatmap shows the free energy of all the mutants analyzed.
[0048] FIG 3 represents the Insulin gene construct in the vector PIL-28a, in accordance with an embodiment of the present disclosure.
[0049] FIG 4 represents the image of PCR amplification of the extracted plasmid using T7 forward and T7 reverse, in accordance with an embodiment of the present disclosure. Lanel: -ve control, Lane2: pET28a T7 amplicon, Lane3: PIL-28a T7 amplicon, Lane4: R22L mutant T7 amplicon.
[0050] FIG 5 represents the Vector map of PIL-28a. The pET28a vector cloned with human proinsulin gene was named PIL-28a, in accordance with an embodiment of the present disclosure.
[0051] FIG 6A displays site-directed mutagenesis of wild-type insulin by designed mutation primers, FIG 6B represents a graph and sequence data, and FIG 6C shows the Lysine addition after methionine in Insulin sequence in PIL-28a by Sanger sequencing, in accordance with an embodiment of the present disclosure.
[0052] FIG 7 represents the image of SDS-PAGE of cell lysate Ni-NTA affinity chromatography, in accordance with an embodiment of the present disclosure.
[0053] FIG 8 represents the image of the digested insulins including mutated glycation-resistant insulin as compared to standard insulin in a 16% Tricine-SDS-PAGE, in accordance with an embodiment of the present disclosure.
[0054] FIG 9 (A and B): represents the image of GLUT4 translocation assay on CHO-HIRc-myc-GLUT4eGFP cells induced by 400nM M197-Proinsulin. (A) 0 min, (B) 24 mins, in accordance with an embodiment of the present disclosure.
[0055] DETAILED DESCRIPTION OF THE INVENTION
[0056] The present invention relates to mutated insulin resistant to glycation, nucleic acids encoding mutated glycation-resistant insulin thereof, method of expressing and producing mutated glycation-resistant insulin thereof; and methods of their use, for example to reduce blood glucose and / or to treat, manage or prevent one or more metabolic diseases in subjects.
[0057] In an embodiment, the present invention provides a recombinant insulin resistant to glycation by site directed mutagenesis of lysine and arginine residues, useful for developing glycation resistant insulin, and proinsulin thereof that have improved stability and activity.
[0058] In an embodiment of the present invention, the mutated glycation-resistant insulin includes mutated glycation-resistant insulin analogues, proinsulin (also referred to as precursor of mutated glycationresistant insulin) expressed and isolated from cell lysates and comprise the undigested C-peptide. In an embodiment of the present invention, the mutated glycation-resistant insulin, mutated glycationresistant insulin analogues, proinsulin (also referred to as precursor of mutated glycation-resistant insulin) which may be long-acting.
[0059] In some embodiments, the mutated insulin of the present invention are insulins that are resistant to glycation (otherwise known as, non-enzymatic glycosylation). The glycation is a chemical reaction between carbohydrate such as glucose with specific amino acid residue of protein e.g. arginine of insulin, resulting in products such as Amadori products, Advanced glycation endproducts (AGEs), etc. via Schiff base as intermediate product, which hamper the activity of insulin by lowering their concentration and also, the glycation products are toxic to human body.
[0060] In an embodiment, the present invention discloses a glycation resistant insulin polypeptide having mutations at site R22 (ARG22) selected from the group consisting of R22A, R22C, R22D, R22E, R22F, R22G, R22H, R22I, R22L, R22M, R22N, R22P, R22Q, R22S, R22T, R22V, R22W, R22Y, R22X, and site K29 (LYS29) selected from the group consisting of K29A, K29C, K29D, K29E, K29F, K29G, K29H, K29I, K29L, K29M, K29N, K29P, K29Q, K29S, K29T, K29V, K29W, K29Y, or K29X wherein X is deletion In another embodiment, said polypeptide is resistant to glycation.
[0061] In some embodiments, said glycation resistant insulin polypeptide is resistant to glycation by 50% to 100%.
[0062] In some embodiments, said glycation resistant insulin polypeptide comprises 1 to 10 amino acid point mutation(s) (such as amino acid substitutions, deletions, additions, or combinations thereof). More preferably at least 1 or at least 2 mutations. More preferably at least 2 mutations (two-point mutations), at amino acids having free amino group, for example lysine (LYS, K) and arginine (ARG, R).
[0063] In an embodiment of the present invention, the mutations are generated by site directed mutagenesis of chain B of insulin peptide by replacing arginine or lysine or both amino acids selectively and, at the same time, maintain equivalent or better efficacy of insulin in terms of glucose control. In an embodiment, mutations are introduced at sites R22 (ARG22), K29 (LYS29), or combinations thereof.
[0064] In one embodiment, the R22 mutations are R22A, R22C, R22D, R22E, R22F, R22G, R22H, R22I, R22L, R22M, R22N, R22P, R22Q, R22S, R22T, R22V, R22W, R22Y, OR R22X where X is deletion.
[0065] In one embodiment, the R22 mutations with K29 mutations are R22A, R22C, R22D, R22E, R22F, R22G, R22H, R22I, R22L, R22M, R22N, R22P, R22Q, R22S, R22T, R22V, R22W, R22Y, OR R22X where X is deletion)
[0066] In one embodiment, the K29 mutations are K29A, K29C, K29D, K29E, K29F, K29G, K29H, K29I, K29L, K29M, K29N, K29P, K29Q, K29S, K29T, K29V, K29W, K29Y, or K29X where X is deletion.
[0067] In one embodiment, the R22 and K29 mutations are in combination by replacing arginine or lysine, and that are covered in table 1 given below:
[0068] Table 1: List of possible combinations done In specific embodiment, the combination of R22 and K29 mutations are selected from (R22A,K29E), (R22S,K29W), (R22N,K29W), (R22N,K29Q), (R22Q,K29E), (R22S,K29Y), (R22Q.K29W),
[0069] (R22N,K29E), (R22N,K29Y), (R22S,K29E) and (R221,K29M).
[0070] Table 2 below provides the Insulin peptide sequences with site directed mutagenesis at R22, or K29. SEQ NOs: 1-9 provide mutant insulin peptides with site directed mutagenesis at R22 and K29, or combinations thereof.
[0071] Table 2: Insulin peptide sequences with site directed mutagenesis at R22 and K29
[0072] *accession no: Sequences of proinsulin. The sequences are submitted at National Center for Biotechnology Information (NCBI) library on 31 January 2023.
[0073] In a preferred embodiment of the present invention, the mutant insulin peptide disclosed herein having a mutation at R22, K29, or combinations thereof (as disclosed in Table 1), and share at least 80% sequence identity to SEQ NO: 1 to SEQ No: 9.
[0074] In another embodiment, the glycation resistant insulin polypeptide disclosed herein having a mutation at R22, K29, or combinations thereof (as disclosed in Table 1), further have one or more mutations (such as a single insertion, a single deletion, a single substitution) at any site apart from the mutations at R22 or K29. Such variant peptides can be produced by manipulating the nucleotide sequence encoding a peptide using standard procedures such as site -directed mutagenesis or PCR In one embodiment, the present invention provides a polynucleotide coding one or more mutated mutant insulin peptides as disclosed in Table 1.
[0075] In one embodiment, the present invention provides a glycation-resistant insulin analog, wherein specific amino acid substitutions are introduced at positions critical for glycation.
[0076] In another embodiment, the present invention provides a method for producing a glycation resistant insulin polypeptide, comprising the steps of: i. identifying and cloning the target gene of insulin; ii. modifying specific amino acid residues of insulin to hinder glycation; iii. expressing the modified insulin precursor peptide sequence in a suitable expression system; iv. purifying the expressed modified insulin precursor peptide sequence to obtain glycation-resistant modified insulin.
[0077] In a preferred embodiment, the present invention discloses a method for producing glycation -resistant insulin, comprising the steps of: i. identifying and cloning target gene of an insulin; ii. modifying amino acid residues R22 and K29 of B -chain of insulin obtaining a modified glycation resistant insulin polypeptide as disclosed above; iii. expressing the modified glycation resistant insulin polypeptide in a suitable expression system; and iv. purifying the expressed modified insulin precursor peptide sequence to obtain glycation-resistant modified insulin.
[0078] In one embodiment, the present invention provides a vector that may also include one or more mutated mutant insulin peptide coding sequences and / or selectable marker genes and other genetic elements known in the art. In an embodiment, the vector can transduce, transform, or infect a cell, thereby causing the cell to express nucleic acids and / or proteins other than those native to the cell.
[0079] In an embodiment, the present invention provides a method of reducing fed and fasting blood glucose, improving insulin sensitivity and glucose tolerance, reducing systemic chronic inflammation, ameliorating hepatic steatosis in a mammal, reducing triglycerides, decreasing insulin resistance, reducing hyperinsulinemia, increasing glucose tolerance, reducing hyperglycemia, reducing food intake, or combinations thereof by administering a therapeutically effective amount of a disclosed mutated glycation-resistant insulin peptide having a mutation at R22, K29, or combinations thereof.
[0080] In one embodiment of the present invention, the nucleic acid encoding a mutant insulin peptide as disclosed in Table 1 can be cloned or amplified by in vitro methods, such as the polymerase chain reaction (PCR), the ligase chain reaction (LCR), the transcription-based amplification system (TAS), the selfsustained sequence replication system (3 SR) and the QP replicase amplification system (QB) or any other in vitro amplification methodologies well known to persons having ordinary skill in the art. Said the nucleic acid can be converted into double stranded DNA by hybridization with a complementary sequence, or by polymerization with a DNA polymerase using the single strand as a template.
[0081] In an embodiment of the present invention, the transgene can be expressed in either prokaryotic or eukaryotic host cells through one or more expression vectors. The expression vectors may further comprise expression control sequences including but not limited to appropriate CMV, EFla, CAG, PGK, TRE, TRE, U6, UAS, T7, Sp6, lac, araBad, trp, Ptac promoters, enhancers, CMV, EFla, CAG, PGK, TRE, TRE, U6, UAS, T7, Sp6, lac, araBad, trp, Ptac transcription terminators, a start codon, splicing signal for introns, maintenance of the correct reading frame of that gene to permit proper translation of mRNA, and stop codons
[0082] In an embodiment of the present invention, the expression vectors include but not limited to pGenLenti, pcDNA, pCI, pCMV, pET, pGEX, pMAL, pMAI, pQE, pGS, pCDF, pRSF, pCOLA, pBac, pAcHLT, pAc, pPIC, pPICZ, pESC, pUC, pBR plasmids, viral vectors, phagemids, yeast expression vectors, and the like.
[0083] In an embodiment of the present invention, the host cells can include but not limited to bacteria, archea, plant, fungal, yeast, insect, and mammalian cells, such as Lactobacillus, Lactococcus, Bacillus (such as B. subtilis), Escherichia (such as E. colt), Clostridium, Saccharomyces or Pichia (such as S. cerevisiae or P. pastoris), Kluyveromyces lactis, Salmonella typhimurium, SF9 cells, C129 cells, 293 cells, Neurospora; and immortalized mammalian myeloid and lymphoid cell lines such as COS, CHO, HeLa and myeloma cell lines.
[0084] In an embodiment of the present invention, the mutated glycation-resistant insulin expressed and purified to obtain the mutant insulin having better stability and glucose-reducing ability for a longer period of time than the native insulin.
[0085] In an embodiment, the present invention relates to a pharmaceutical composition comprising the mutated glycation-resistant insulin or proinsulin thereof as described above for the ‘management’, ‘prevention’ or ‘treatment’ of one or more metabolic diseases in subjects, preferably diabetes.
[0086] In an embodiments, the diabetes is selected from but not limited type 2 diabetes, non-type 2 diabetes, type 1 diabetes, latent autoimmune diabetes (LAD), or maturity onset diabetes of the young (MODY), metabolic syndrome (MetS), obesity, non-alcoholic steatohepatitis (NASH), dyslipidemia (e.g., hyperlipidemia), and the like.
[0087] In an embodiment of the present invention, the pharmaceutical composition comprising the mutated glycation-resistant insulin or proinsulin thereof can be administered in combination with effective doses of anti-diabetic agents (such as biguanides, thiazolidinediones, or incretins) and / or lipid lowering compounds (such as statins or fibrates). Antidiabetic agents for example, insulin, metformin, sulphonylureas, nateglinide, repaglinide, thiazolidinediones, peroxisome proliferator-activated receptor (PPAR)-gamma-agonists and antagonists, PPAR-gamma / alpha modulators, alpha-glucosidase inhibitors, Dipeptidyl peptidase (DPP)-IV inhibitors, alpha2-antagonists, agents for lowering blood sugar, cholesterol-absorption inhibitors, 3-hydroxy-3-methylglutaryl-coenzyme A (HMGCoA) reductase inhibitors, insulin and insulin analogues, GLP-1 and GLP-1 analogues (e.g., exendin-4) or amylin.
[0088] In an embodiment of the present invention, the terms, ‘management’, ‘prevention’ or ‘treatment’ as used herein refers to alleviate, slow the progression, attenuation, prophylaxis or as such treat the existing disease or condition. Treatment also includes treating, preventing development of, or alleviating to some extent, one or more of the symptoms of the diseases or condition.
[0089] In an embodiment of the present invention, the term, "subject" as used herein refers to an animal, preferably a mammal, and most preferably a human. The term "mammal" used herein refers to warmblooded vertebrate animals of the class 'mammalia' , including humans, characterized by a covering of hair on the skin and, in the female, milk-producing mammary glands for nourishing the young, the term mammal includes animals such as cat, dog, rabbit, bear, fox, wolf, monkey, deer, mouse, pig and human.
[0090] In an embodiment of the present invention, the pharmaceutical composition comprising the mutated glycation-resistant insulin or proinsulin thereof can be formulated as a pharmaceutical formulation for delivery by an oral, intravenous, intramuscular, intra-arterial, intramedullary, intrathecal, subcutaneous, intraventricular, transdermal, interdermal, rectal, intravaginal, intraperitoneal, topical, transdermal, mucosal, ear, nasal, buccal, enteral, or sublingual route. In an embodiment, the pharmaceutical formulation of this invention may further comprise a pharmaceutically acceptable excipient. The excipient may be selected from the group comprising of flavonoids, diluents, stabilizers, binders, flavoring agents, thickeners, coloring agents, humectants, preservatives, olfactory agents, and combinations thereof.
[0091] In an embodiment of the present invention, the pharmaceutical composition comprising the mutated glycation-resistant insulin or proinsulin thereof may further comprise one or more additional therapeutic agents selected from but not limited to ace -inhibitors, anti-Alzheimer's agents, antianginal drugs, antiarrhythmias, anti-asthmatics, anti-cholesterolemics, analgesics, anesthetics, anti-convulsants, antidepressants, antipsychotics, anti-diabetic agents, anti-diarrhea preparations, antidotes, anti-emetics, antihistamines, anti-hypertensive drugs, anti-inflammatory agents, anti-lipid agents, anti-manics, antimigraines, anti-nauseants, anti-stroke agents, anti-thyroid preparations, anti-tumor drugs, anti-viral agents, acne drugs, alkaloids, amino acid preparations, anti-tussives, anti-uricemic drugs, anti-viral drugs, anabolic preparations, systemic and non-systemic anti-infective agents, anti-neoplastics, antiparkinsonian agents, anti-rheumatic agents, anxiolytics, anti-psychotics, appetite stimulants, biological response modifiers, blood modifiers, bone metabolism regulators, bronchodilators, cardiovascular agents, central nervous system stimulates, cholinesterase inhibitors, contraceptives, decongestants, dietary supplements, dopamine receptor agonists, endometriosis management agents, enzymes, erectile dysfunction agents, fertility agents, gastrointestinal agents, H2-antagonists, homeopathic remedies, hormones, hypercalcemia and hypocalcemia management agents, immunomodulators, immunosuppressives, migraine preparations, motion sickness treatments, muscle relaxants, non-steroidal anti-inflammatories (NSAID's), obesity management agents, osteoporosis preparations, oxytocics, parasympatholytics, parasympathomimetics, prostaglandins, psychotherapeutic agents, respiratory agents, sedatives, serotonin 5-HT3 receptor antagonists, smoking cessation aids, sympatholytics, tremor preparations, urinary tract agents, vasodilators, laxatives, antacids, ion exchange resins, anti-pyretics, appetite suppressants, expectorants, anti-anxiety agents, anti-ulcer agents, anti-inflammatory substances, coronary dilators, cerebral dilators, peripheral vasodilators, psycho-tropics, stimulants, anti-hypertensive drugs, vasoconstrictors, migraine treatments, antibiotics, tranquilizers, anti-psychotics, anti-tumor drugs, anti-coagulants, anti-thrombotic drugs, hypnotics, anti-emetics, anti-nauseants, anti-convulsants, neuromuscular drugs, hyper- and hypo-glycemic agents, thyroid and anti-thyroid preparations, diuretics, anti-spasmodics, anti-obesity drugs, erythropoietic drugs, anti-asthmatics, cough suppressants, mucolytics, DNA and genetic modifying drugs, and combinations thereof.
[0092] In an embodiment of the present invention, the pharmaceutical formulation comprises the mutated glycation-resistant insulin or proinsulin thereof at a therapeutically effective concentration or amount.
[0093] Procurement Details:
[0094] 1. Human proinsulin gene containing plasmid (pLX304) - transOMIC Technologies Inc., USA.
[0095] 2. pET-28a vector - Merck, USA.
[0096] 3. Restriction endonucleases Ndel and Xhol - New England Biolabs Inc., USA.
[0097] 4. DH5a competent cells - New England Biolabs Inc., USA.
[0098] 5. LB agar / broth - HiMedia, India.
[0099] 6. Kanamycin - Gibco, USA.
[0100] 7. T7 forward-reverse primer - IDT, USA.
[0101] 8. Taq DNA polymerase - Takara Biosciences, Japan.
[0102] 9. SHuffle® T7 Competent E. coli - New England Biolabs Inc., USA.
[0103] 10. Luria Bertani (LB) media - HiMedia, India.
[0104] 11. IPTG (isopropylthio-P-galactoside) - Sigma, USA.
[0105] 12. Tris - Sigma, USA.
[0106] 13. Phenylmethylsulfonyl fluoride (PMSF) - Sigma, USA.
[0107] 14. Guanidine hydrochloride - SRL, India. 15. P-mercaptoethanol (BME) - Sigma, USA.
[0108] 16. Glycine - Sigma, USA.
[0109] 17. Cysteine hydrochloride - SRL, India.
[0110] 18. Cystine - SRL, India.
[0111] 19. EDTA - SRL, India.
[0112] 20. Trypsin protease - Sigma, USA.
[0113] 21. Tricine - SRL, India.
[0114] 22. CHO-HIRc-myc-GLUT4eGFP cells is same as referred in Vijayakumar, M. V. et al., Journal of biosciences, 35, 2010, pages 525-531.
[0115] 23. Ham’s F12 media - Gibco, USA.
[0116] 24. Fetal Bovine Serum - Gibco, USA.
[0117] 25. Gentamicin - Gibco, USA.
[0118] EXAMPLES
[0119] The present invention is further explained in the form of following examples. However, it is to be understood that the foregoing examples are merely illustrative and are not to be taken as limitations upon the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art. Such changes and modifications may be made without departing from the scope of the invention.
[0120] Example 1: Mutations and stability analysis
[0121] The Hexameric structure of human insulin PDB ID: 4eww was retrieved from the RCSB-PDB database and used. Mutations were performed at two sites which are prone to glycation ARG22 (R22) and LYS29 (K29) of insulin and were carried out using Position Specific Scoring Matrices (PSSM) algorithm of FoldX suite. It mutates selected positions to a list of provided residues and calculates the difference of free energies (DDG) upon mutation. The stable mutants were sorted and selected based on their total energy.
[0122] R22 and K29 mutations were analyzed using two tools. SDM server calculated the free energy change for the amino acid variations at these positions (Table 1) and 5 most stable variants at each position were selected to proceed with site directed mutagenesis.
[0123] Analysis was done using insilico based stability analysis using FoldX. The free energy (DDG / AAG) is a metric for predicting how a single point mutation will affect protein stability. Negative DDG suggests that the mutation would lead to a more stable protein. The DDG <0 kJ / mol were considered most stable among the mutants. The heatmap shown in FIG. 2 shows the free energy of all the mutants analyzed. For initial screening, the 10 most stable mutants with negative DDG were selected (Table 3) for expression. The in silica mutations and their free energy values are given in the supplementary table.
[0124] Table 3: Free energy change after amino acid mutation predicted by SDM tool
[0125] Table 4: Selected mutations from FoldX analysis.
[0126] Example 2: Cloning strategy
[0127] The human proinsulin gene containing plasmid (pLX304) was procured from transOMIC Technologies Inc. (USA). The human insulin gene was PCR amplified and subcloned into pET-28a vector (FIG. 1) using Restriction digestion based cloning. The PCR product was purified and digested by restriction endonucleases Ndel and Xhol at 37°C for 3 hrs followed by ligation at 16°C overnight.
[0128] The DH5 a competent cells were transformed with the above ligation mixture and plated on LB agar plates with kanamycin resistance. The plates were then incubated at 37°C overnight. The following day, positive colonies observed on the plates were screened by colony PCR method. Briefly, 20 colonies were picked by touching a pipette tip to the surface of the colony, and the cells that attached to the tip were resuspended in PCR master mix. PCR was carried out using gene-specific forward primer and vector-specific reverse primer (T7 forward-reverse for pET-28a) with Taq DNA polymerase (New England Biolabs Inc., USA). The colonies that showed positive amplification were inoculated into 5ml LB broth with kanamycin and grown overnight at 37°C. The following day, cells were centrifuged and plasmids were extracted using QIAprep Spin Miniprep Kit (Qiagen, Germany). The plasmid concentration was determined using Nanodrop™ spectrophotometer and further subjected to restriction digestion to confirm the presence of insert. Plasmid samples were also submitted for sequencing (Eurofins Genomics India Pvt. Ltd., Bangalore) for validation.
[0129] The pET28a vector cloned with human proinsulin gene was named PIL-28a (FIG. 3) and its sequence map is as shown in FIG. 5. The colony PCR showed the insertion of gene between the T7 forward and T7 reverse primers as the size of the amplicon was increased as shown in FIG. 4. The cloned plasmid sequence was confirmed by Sanger sequencing using primers T7 forward and T7 reverse. The lysine addition after methionine was confirmed by Sanger sequencing as shown in FIG. 6.
[0130] Examaple 2.1 Site-directed mutagenesis (SDM):
[0131] Primer Design
[0132] SnapGene Viewer was used for peptide designing. Briefly, the pET28a vector containing the Proinsulin gene was loaded into the software. The primers were designed with parameters such as a length of not more than 35 bases, melting temperature in the range 65 ± 5 °C, specificity to only coding region in the plasmid, and 3’ overhangs compared to the complementary reverse sequence. The triplet codon coding for the R22 and K29 were replaced by other respective amino acids. The primer sequences are given in the following table, along with the length.
[0133] Table 4.1: Designed primers for SDM
[0134]
[0135] Mutation PCR
[0136] The lyophilized primers were reconstituted with nuclease -free water. The reaction constituents were as follows; IX ExTaq buffer, 0.25pM dNTPs, 0.5pM forward and reverse primers each, and 1.25U ExTaq polymerase. The reaction parameters are shown in Table 4.2. The extension time was calculated based on plasmid size and 1Kb per minute.
[0137] Table 4.2: PCR parameters for SDM.
[0138] After the mutation PCR, the template strand was digested using the Dpnl restriction enzyme, which is a type IIM restriction enzyme that digests methylated DNA. The digestion was carried out at 37°C for 1 hour. After Dpnl treatment, the enzyme was deactivated by heating at 70°C for 10 mins. The resultant product was used for transformation into cloning cells. The sequence was confirmed using Sanger sequencing and the results are mentioned in the Fig. 6.
[0139] Example 3: Expression, extraction and purification
[0140] SHuffle® T7 Competent E. coli (NEB, USA) was transformed with PIL-28a (Proinsulin in pET28a) for proinsulin expression. Positive colonies were evaluated for Proinsulin expression. The colonies were inoculated in 10ml Luria Bertani (LB) media along with 50 ug / ml kanamycin and incubated overnight at 37°C in a shaker incubator. This primary culture was inoculated in 100ml LB media with 50 pg / ml kanamycin. Induction was done by 0.5mM IPTG (isopropylthio-P-galactoside) when the ODeoo of the culture reached 0.4. After induction the culture was incubated at 25°C for 4 hours in a shaker incubator. After expression, the secondary culture was centrifuged at 4000xg for 10 mins at room temperature. The supernatant media was discarded and the cell pellet was redissolved in 50mM Tris pH 9.0 with 2mM phenylmethylsulfonyl fluoride (PMSF). Lysis of the cell mass was carried out using a sonication probe with 90% amplitude for 10 mins (10 secs on and 10 secs off). After sonication the cell lysate was centrifuged at lOOOOxg for 15 mins at 4°C. The supernatant and the inclusion body pellet resuspended in a buffer were loaded in a 15% SDS-PAGE to check proinsulin overexpression.
[0141] Proinsulin extraction and purification- Proinsulin in the cell lysate supernatant was purified using Ni- NTA affinity chromatography. The supernatant was incubated with Ni-NTA agarose resin for 2 hours at room temperature on a rotor shaker. Non-specific binding was washed with 20mM imidazole in 50mM Tris pH 9.0 and bound proinsulin was eluted in 250mM imidazole in 50mM Tris buffer pH 9.0. The eluted fractions were concentrated using 3KDa cutoff microcentrifuge columns.
[0142] Proinsulin in the inclusion bodies (IB) was denatured with 6M Guanidine hydrochloride and ImM P- mercaptoethanol (BME) on continuous stirring for 4 hours at room temperature. The denatured IB was purified by Ni-NTA affinity chromatography as previous with addition of 6M Guanidine hydrochloride and lmM BME in the washing and elution buffer.
[0143] Refolding of Proinsulin from inclusion bodies- Denatured Proinsulin was subjected to refolding. For the refolding buffer, lOmM Glycine-NaOH buffer pH 10.0, 0.5mM cysteine hydrochloride, 4.5mM cystine, lmM EDTA was used. The denatured Proinsulin was diluted 20 fold using the refolding buffer and kept for continuous stirring at 4°C. Samples were aliquoted at 24 hours, 48 hours, 72 hours and 90 hours and checked for refolding in Gel Filtration Chromatography (Superdex 75, GE healthcare). The protein was concentrated using a 3KDa cut off column.
[0144] Conversion of Proinsulin to Insulin- The supernatant elution and refolded protein was subjected to digestion by trypsin (T6567, Sigma) protease. The trypsin specifically cleaves at the C-terminal of arginine and lysine. This cleaves off the N-terminal 6xhis tag and C-peptide. The enzyme to protein ratio was incubated at 37°C for 3 hours, 6 hours, 9 hours, and 12 hours with the ratio 1:400. The reaction was stopped using 2% formic acid. The digested proinsulin was then concentrated with a 3KDa cut off microcentrifuge column and mature insulin was retained.
[0145] The SHuffle® T7 Competent E. coli cells produced about 2 grams of cell mass per litre of media. The Ni-NTA affinity chromatography successfully separated overexpressed proinsulin from the cell lysate which was confirmed by SDS-PAGE as shown in FIG. 7. The proinsulin was quantified using Bradford assay. From 1 litre media, around 380ug of protein was extracted in soluble fraction of the cell lysate which was further subjected to conversion to insulin using trypsin digestion.
[0146] Example 4 : Characterization Of Digested Insulin
[0147] The digested proinsulin was analyzed by 16% Tricine-SDS-PAGE and MALDI-ToF MS. Tricine-SDS- PAGE is the preferred electrophoretic system for the resolution of proteins smaller than 30 kDa. For MALDI-ToF MS analysis, the matrix used was Sinapic acid in the ratio 1:20 for protein to matrix. The acquisition was done in both linear and reflector mode with positive polarity. The range was 2000 Da to 15000 Da.
[0148] The digestion of proinsulin was checked with 16% Tricine SDS-PAGE and MALDI-ToF MS. In FIG. 8, the mutant mature insulin is compared to standard insulin in a Tricine-SDS-PAGE. The calculated masses of the mutated proinsulin and digested proinsulin and peptides are given in (Table 5). Similarly, the MALDI-ToF analysis gave the peak of undigested proinsulin and mature insulin at 11604.5342 Da and 5642.6548 Da respectively.
[0149] Table 5: Calculated masses of the mutant and digested proinsulin and peptides.
[0150] Example 5: GLUT4 translocation assay
[0151] In the GLUT4 translocation assay, CH0-HIRc-myc-GLUT4eGFP cells (Passage No - 13) were used, overexpressing Insulin Receptor (IR) and GFP-tagged GLUT4 protein. The cells were allowed to grow in a P35 petri plate (Tarson) till 70% confluency in Ham’s F12 media (Gibco) supplemented with 10% fetal bovine serum (Gibco) and gentamycin (Gibco) concentration of 2ug / ml. The cells were serum starved with serum-free Ham’s F12 media for 3 hours for cell cycle arrest. The plate was observed under EVOS Fl (Thermofischer scientific) fluorescent microscope. A field was chosen based on the cell density and was fixed at 40X magnification. Then the cells were treated with 400nM Ml 97 mutant insulin. The image was captured at a 3-minute interval for 30 mins. The cells shown in FIG. 9A show the GLUT4 protein in the nuclear periphery. In FIG. 9B, after administration of Ml 97 mutant insulin, the GLUT4 can be observed at the cell membrane. This suggests that M197 activates the insulin signaling cascade by binding to the insulin receptor, thus translocating the GLUT4 from the nuclear periphery to the cell membrane and helping in glucose uptake.
[0152] ADVANTAGES OF THE PRESENT INVENTION:
[0153] The present invention provides a replacement of lysine and arginine residues of insulin with other amino acids without compromising the activity and will circumvent the problem of glycation. The present invention provides a development of glycation resistant proteoforms of insulin with better treatment efficiency in diabetes. The present invention provides a strategy for development of glycation resistant proteoforms which can be further used for development of long acting glycation resistant insulin.
Claims
AMENDED CLAIMS received by the International Bureau on 18 September 2024 ( 18.09.2024)1. A glycation resistant insulin polypeptide having two-point mutations at site R22 (ARG22) selected from the group comprising of R22A, R22C, R22D, R22E, R22F, R22G, R22H, R22I, R22L, R22M, R22N, R22P, R22Q, R22S, R22T, R22V, R22W, R22Y, R22X, and at site K29 (LYS29) selected from the group comprising of K29A, K29C, K29D, K29E, K29F, K29G, K29H, K29I, K29L, K29M, K29N, K29P, K29Q, K29S, K29T, K29V, K29W, K29Y, and K29X, wherein X is designated as deletion of amino acid sequence.
2. The polypeptide as claimed in claim 1, wherein said polypeptide is having sequences selected from SEQ ID NO: 1 to SEQ ID NO: 9.
3. The polypeptide as claimed in claim 1, wherein the mutations at site R22 are selected from the group consisting of R22A, R22S, R22N, R22Q, and the mutations at site K29 are selected from the group consisting of K29E, K29W, K29Q and K29Y.
4. The polypeptide as claimed in claim 1, wherein the polypeptide is resistant to glycation by 50% to 100%.
5. The polypeptide as claimed in claim 1, wherein said polypeptide comprises 1 to 10 amino acid substitutions.
6. The polypeptide as claimed in claim 1, wherein the polypeptide having a mutation at R22, K29, or combinations thereof share at least 80% sequence identity to SEQ NO: 1 to SEQ NO: 9.
7. A polynucleotide coding one or more mutated mutant insulin polypeptides as claimed in claim 1.
8. A method for producing glycation-resistant insulin, comprising the steps of: i. identifying and cloning target gene of an insulin; ii. modifying amino acid residues R22 and K29 of B -chain of insulin obtaining a modified glycation resistant insulin polypeptide as claimed in claim 1 ;18AMENDED SHEET (ARTICLE 19)iii. expressing the modified glycation resistant insulin polypeptide in a suitable expression system; and iv. purifying the expressed modified insulin precursor peptide sequence to obtain glycation-resistant modified insulin.
9. The method as claimed in claim 7, wherein the modification of step ii) in said polypeptide is generated by site directed mutagenesis of chain B of insulin peptide by substituting arginine at R22 or lysine at K29 or both amino acids selectively.
10. A pharmaceutical composition comprising the polypeptide as claimed in claim 1 or claim 2 and one or more of a pharmaceutically acceptable excipient selected from the group comprising of flavonoids, diluents, stabilizers, binders, flavoring agents, thickeners, coloring agents, humectants, preservatives, olfactory agents, and combinations thereof.
11. A method of reducing blood glucose level in a diabetic subject by administering a therapeutically effective amount of the polypeptide as claimed in claim 1 or claim 2.AMENDED SHEET (ARTICLE 19)
